Risk factors for extended-spectrum beta-lactamase-producing Enterobacteriaceae in community-acquired urinary tract infections in children and susceptibility to commonly used antibiotic treatments

Author:

Rizik Suha1,Kassis Imad1,Makhoul Nadeen1,Dabaja-Younis Halima2

Affiliation:

1. Ruth Rappaport Children's Hospital, Rambam Health Care Campus

2. Technion–Israel Institute of Technology Haifa

Abstract

Abstract Purpose Enterobacteriaceae producing extended-spectrum beta-lactamase (ESBL) are common pathogens of UTI in children and their prevalence is increasing worldwide. The aim of this study was to determine risk factors for ESBL-positive UTI and susceptibility to antibiotic treatments. Methods A retrospective cohort study conducted at Rambam Health Care Campus, a tertiary hospital in northern Israel. The study included patients younger than < 18 years old and ESBL positive UTI between January 2017 and December 2019. Patient demographics, previous antibiotic treatment, previous UTI episode, genitourinary tract abnormalities, identified organisms in urine cultures, and sensitivity to antibiotics were recorded. Results A total of 570 children who contributed 639 episodes of community-acquired ESBL UTI with 661 Enterobacteriaceae isolates. The median age was 1.3(IQR:0.69–5.9) years. Female comprised 87.9% of the patients. ESBL isolates were identified in 56 (9.8%) patients. Higher rates of resistance to oral antibiotic treatments were found in the ESBL-positive group compared to the ESBL-negative group; amoxicillin-clavulanic acid (65.2% vs 22.7%, p < 0.001, OR = 6.84), trimethoprim-sulfamethoxazole (59.4% vs 17.6%, p < 0.001, OR = 6.84), ciprofloxacin (34.8% vs 4.5%, p < 0.001, OR = 11.43), and to piperacillin-tazobactam (27.5% vs 6.4%, p < 0.001, OR = 5.54). Neither group was resistant to amikacin or carbapenem. Risk factors for ESBL-positive UTI were antibiotic treatment within the last three months (p = 0.002, OR = 3.68, CI:1.63–8.31) and known ESBL carriage (p < 0.001, OR = 13.18, CI:4.25–40.94). Conclusions Known ESBL carriage and recent antibiotic treatment were risk factors for ESBL UTI. High rate of resistance to oral empiric and prophylactic antibiotic treatments was detected. Amikacin as initial treatment in anticipation of culture susceptibility is reasonable.

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3